Company Quick10K Filing
Immunocellular Therapeutics
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 42 $10
10-Q 2018-08-13 Quarter: 2018-06-30
10-Q 2018-05-14 Quarter: 2018-03-31
10-K 2018-03-14 Annual: 2017-12-31
10-Q 2017-11-21 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-09 Annual: 2016-12-31
10-Q 2016-11-10 Quarter: 2016-09-30
10-Q 2016-08-22 Quarter: 2016-06-30
10-Q 2016-05-13 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-09 Quarter: 2015-09-30
10-Q 2015-08-07 Quarter: 2015-06-30
10-Q 2015-05-11 Quarter: 2015-03-31
10-K 2015-03-10 Annual: 2014-12-31
10-Q 2014-11-10 Quarter: 2014-09-30
10-Q 2014-08-08 Quarter: 2014-06-30
10-Q 2014-05-09 Quarter: 2014-03-31
10-K 2014-03-14 Annual: 2013-12-31
10-Q 2013-11-07 Quarter: 2013-09-30
10-Q 2013-08-08 Quarter: 2013-06-30
10-Q 2013-05-10 Quarter: 2013-03-31
10-K 2013-03-11 Annual: 2012-12-31
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-11 Quarter: 2012-03-31
10-K 2012-03-21 Annual: 2011-12-31
10-Q 2011-11-14 Quarter: 2011-09-30
10-Q 2011-08-18 Quarter: 2011-06-30
10-Q 2011-05-16 Quarter: 2011-03-31
10-K 2011-03-31 Annual: 2010-12-31
10-Q 2010-11-15 Quarter: 2010-09-30
10-Q 2010-08-16 Quarter: 2010-06-30
10-Q 2010-05-18 Quarter: 2010-03-31
10-K 2010-03-31 Annual: 2009-12-31
8-K 2018-10-16 Exhibits
8-K 2018-10-10 Officers, Exhibits
8-K 2018-08-13 Earnings, Exhibits
8-K 2018-05-14 Earnings, Exhibits
8-K 2018-03-13 Earnings, Exhibits
8-K 2018-02-13 Earnings, Exhibits
8-K 2018-01-29 Officers

Immunocellular Therapeutics Financials

IMUC Metrics, Comps, Filings

Annual | Quarterly

Business

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which the immune system uses to identify foreign bodies. While some other cancer immunotherapies target only a single cancer antigen, our technology can elicit an immune response against several antigens simultaneously. Our clinical stage cancer immunotherapy programs are also distinguished by the fact that they target cancer stem cells (CSCs), which are the primary drivers of tumor growth and disease recurrence.

Review of Strategic Alternatives

We expect to devote substantial time and resources to exploring strategic alternatives that our board of directors believes will maximize stockholder value. Our consideration of strategic alternatives includes, but is not limited to, the potential for an acquisition, merger, business combination, licensing and/or other strategic transaction involving the company. Despite devoting significant efforts to identify and evaluate potential strategic transactions, we may not be successful in completing a transaction. Further, even if a strategic transaction is completed, it ultimately may not deliver the anticipated benefits or enhance stockholder value.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Sino Agro Food (SIAF) 10,995 16% 0.8 2% 794,381 80,166 141,804 22,000 19,515 19,860 15,742
New Bancorp (NWBB) 10,731 -1.6 0% 117,804 101,893 0 0 398 1,869 -3,046
Kiwa Bio-Tech (KWBT) 10,716 34% 9.7 -3% 32,244 19,141 28,194 9,701 -929 1,295 12,518
BioCorRx (BICX) 10,699 55% -1.0 -148% 5,512 260 262 143 -8,172 -6,054 5,906
Zenosense (ZENO) 10,638 -48.7 -112% 413 756 0 0 -464 -227 11,055
Applied Minerals (AMNL) 10,531 0% 7.6 291% 2,076 43,967 5,075 0 6,034 6,859 52,112
KinerjaPay (KPAY) 10,487 2% -0.7 -361% 4,481 7,603 794 18 -16,156 -16,130 10,515
Immunocellular Therapeutics (IMUC) 10,478 -1.3 -148% 3,829 402 0 0 -5,664 -5,664 7,626
Parks America (PRKA) 10,475 0% 4.2 11% 10,279 1,882 6,221 0 1,120 2,045 8,650
Sci Engineered Materials (SCIA) 10,472 22% 10.1 10% 8,241 4,340 13,728 3,044 831 862 8,674
International Baler (IBAL) 10,420 32% 13.6 2% 10,305 1,034 5,535 1,774 242 489 6,629
Duo World (DUUO) 10,418 61% -15.4 -62% 1,130 4,499 667 404 -698 -677 10,409
Sunstock (SSOK) 10,414 10% -2.4 -691% 654 5,532 1,928 184 -4,520 -4,317 10,394
Dais Analytic (DLYT) 10,399 50% -6.7 -771% 393 7,194 1,044 520 -3,025 -1,540 10,370
AlphaPoint Technology (APPO) 10,360 0% -10.9 -1,370% 69 987 10 0 -948 -948 10,324
Nanoflex Power (OPVS) 10,175 0% -0.9 -3,712% 442 11,151 627 0 -16,426 -11,456 10,074
Global Healthcare REIT (GBCS) 10,120 0% 66.3 -3% 39,953 38,819 2,890 0 -1,306 710 47,097
Home Treasure Finders (HMTF) 10,092 0% -1,769.4 -5% 869 992 686 0 -47 -6 10,063
SPYR (SPYR) 10,003 143% -4.1 -819% 375 3,839 252 361 -3,073 -2,421 9,980
Sunwin Stevia (SUWN) 9,982 10% -2.0 -13% 30,813 27,391 19,835 2,035 -4,101 -4,588 9,196

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash6,65326,21727,64623,22222,60411,4376,630
Accounts Receivable
Inventory
PP&E7676185471811101
Assets7,15127,01928,94125,17930,08216,8907,009
Accounts Payable1,3177338613221,1611,3421,775
Long-Term Debt4,1346,9460
Liabilities3,9193,9512,4671,8878,36210,7582,361
Stockholders' Equity3,23223,06826,47423,29221,7206,1324,648
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Revenue000000
Cost of Revenue
Gross Profit
R&D4,9897,7115,3405,96910,89719,10617,126
SG&A2,4473,6193,3963,2354,6165,0064,027
Tax000000
Net Income-5,720-14,495-8,801-9,378-12,791-22,086-14,312
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-31
Cash Operating-6,384-12,380-8,787-9,937-19,039-19,864-16,672
Cash Investing-84-10-44-29-170-41
Cash Financing7,80231,95310,2615,54118,5918,70111,863